Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SER 100

Drug Profile

SER 100

Alternative Names: SER-100; SER100 PH; SER100 TR-ISH; ZP-120

Latest Information Update: 19 Jul 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Zealand Pharma
  • Developer Serodus; Zealand Pharma
  • Class Oligopeptides; Peptides
  • Mechanism of Action Nociceptin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pulmonary arterial hypertension
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Isolated systolic hypertension
  • Phase I Pulmonary hypertension
  • Discontinued Decompensated heart failure

Most Recent Events

  • 16 Jan 2016 Phase-I clinical trials in Pulmonary hypertension (In volunteers) in Norway (IV) before January 2016
  • 09 Sep 2014 Efficacy and adverse events data from a phase IIa trial in Isolated systolic hypertension released by Serodus
  • 01 Sep 2014 Serodus completes a phase IIa trial in Isolated systolic hypertension (Treatment-resistant, In the elderly) in Finland, Hungary, Norway and United Kingdom (NCT01987284)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top